Canada Communicable Disease Report最新文献_第3页

Does the Australian influenza season predict the Canadian influenza season? A qualitative comparison of seasons, 2014–2020 澳大利亚流感季节能否预测加拿大流感季节？2014-2020 年流感季节的定性比较

Canada Communicable Disease Report Pub Date : 2023-12-22 DOI: 10.14745/ccdr.v49i1112a05

Deborah Chan, Liza Lee, C. Bancej

引用次数: 0

Mycoplasma genitalium infection among gay, bisexual and other men who have sex with men in Montréal, Canada 加拿大蒙特利尔男同性恋、双性恋和其他男男性行为者的生殖器支原体感染情况

Canada Communicable Disease Report Pub Date : 2023-12-22 DOI: 10.14745/ccdr.v49i1112a03

Anne-Sophie Lê, Annie-Claude Labbé, A. Fourmigue, Milada Dvorakova, Joseph Cox, Claude Fortin, Irene Martin, Daniel Grace, Trevor Hart, David Moore, Gilles Lambert

引用次数: 0

Syndromic surveillance performance in Canada throughout the COVID-19 pandemic, March 1, 2020 to March 4, 2023 2020 年 3 月 1 日至 2023 年 3 月 4 日 COVID-19 大流行期间加拿大的综合监控表现

Canada Communicable Disease Report Pub Date : 2023-12-22 DOI: 10.14745/ccdr.v49i1112a06

Myriam Ben Moussa, Abbas Rahal, Liza Lee, Shamir Mukhi

引用次数: 0

National Influenza Annual Report, Canada, 2022–2023: Canada’s first fall epidemic since the 2019–2020 season 加拿大 2022-2023 年全国流感年度报告：加拿大自 2019-2020 年流感季节以来首次出现秋季流行病

Canada Communicable Disease Report Pub Date : 2023-11-20 DOI: 10.14745/ccdr.v49i10a02

Kara Schmidt, Myriam Ben Moussa, S. Buckrell, Abbas Rahal, Taeyo Chestley, Nathalie Bastien, L. Lee

引用次数: 0

Current and future burden from Lyme disease in Québec as a result of climate change 气候变化对魁北克莱姆病当前和未来造成的负担

Canada Communicable Disease Report Pub Date : 2023-11-20 DOI: 10.14745/ccdr.v49i10a06

M. Ripoche, Alexandra Irace-Cima, Ariane Adam-Poupart, Geneviève Baron, Catherine Bouchard, Alex Carignan, François Milord, N. Ouhoummane, Pierre Pilon, Karine Thivierge, Kate Zinszer, Diane Chaumont

{"title":"Current and future burden from Lyme disease in Québec as a result of climate change","authors":"M. Ripoche, Alexandra Irace-Cima, Ariane Adam-Poupart, Geneviève Baron, Catherine Bouchard, Alex Carignan, François Milord, N. Ouhoummane, Pierre Pilon, Karine Thivierge, Kate Zinszer, Diane Chaumont","doi":"10.14745/ccdr.v49i10a06","DOIUrl":"https://doi.org/10.14745/ccdr.v49i10a06","url":null,"abstract":"Context: Environmental changes will foster the spread of Ixodes scapularis ticks and increase the incidence of Lyme disease in Québec in the coming years. The objective of this study is to estimate the epidemiological and clinical burden and part of the current economic burden of Lyme disease in Québec and to estimate the number of cases expected by 2050. Methods: Cases of Lyme disease reported in Québec from 2015 to 2019 were used to describe their demographic, geographical and clinical characteristics and the cost of their initial care. Three incidence rate scenarios were then developed to estimate the number of cases expected by 2050, based on demographic and climate projections. Results: From 2016 to 2019, 1,473 cases of Lyme disease were reported in Québec. Over 90% of those cases were acquired in two regions of southern Québec (Estrie and Montérégie), while the individuals infected were residents from all over Québec. The average age of cases is 44 years and 66% of infections were at the localized stage, the first stage of Lyme disease. The cost of initial care is estimated at an average of $182 CAN per patient ($47 CAN at the localized stage and $443 CAN at the disseminated stage). According to projections, over 95% of the Québec population will live in a climate zone conducive to the establishment of ticks by 2050, with a number of cases acquired in Québec being 1.3 to 14.5 times higher than in 2019, depending on the incidence rate scenario used. Conclusion: The epidemiological burden is concentrated primarily in southern Québec, but the clinical and economic burden is already distributed throughout the province. The projections for 2050 should help the regions of Québec adapt and optimize public health protection measures.","PeriodicalId":33496,"journal":{"name":"Canada Communicable Disease Report","volume":"20 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139257538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Influenza vaccines may protect against cardiovascular diseases: The evidence is mounting and should be known by the Canadian public health community 流感疫苗可预防心血管疾病：证据越来越多，加拿大公共卫生界应了解这些证据

Canada Communicable Disease Report Pub Date : 2023-11-20 DOI: 10.14745/ccdr.v49i10a04

Philippe De Wals, Michaël Desjardins

{"title":"Influenza vaccines may protect against cardiovascular diseases: The evidence is mounting and should be known by the Canadian public health community","authors":"Philippe De Wals, Michaël Desjardins","doi":"10.14745/ccdr.v49i10a04","DOIUrl":"https://doi.org/10.14745/ccdr.v49i10a04","url":null,"abstract":"Evidence on the protective effect of influenza vaccines to prevent cardiovascular disease (CVD) is mounting. We identified 28 systematic reviews/meta-analyses on the effect of influenza vaccines on CVD using different research questions, data sources, selection criteria and outcomes. Most results leaned towards a protective effect. Results of recently published experimental and observational studies not included in these reviews were going in the same direction. The evidence is very robust for cardiovascular deaths and nonfatal myocardial infarction in high-risk individuals, but lower for heart failure, arrhythmia, and stroke and also for all outcomes in low-risk adults. There is also limited evidence for pneumococcal polysaccharide vaccines and evidence has to be collected from ongoing trials on respiratory syncytial virus vaccines. Up to now, this effect has not been considered in economic evaluations of influenza vaccines and its inclusion may change CVD results markedly. This effect is not mentioned in the Canadian Immunization Guide and not known by a majority of vaccinators. The objective of this short commentary is to alert the Canadian public health community and to provide information that could be used at the field level to promote the usefulness of influenza vaccines.","PeriodicalId":33496,"journal":{"name":"Canada Communicable Disease Report","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139255930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2023–2024 国家免疫咨询委员会（NACI）2023-2024 年季节性流感疫苗声明摘要

Canada Communicable Disease Report Pub Date : 2023-11-20 DOI: 10.14745/ccdr.v49i10a01

Angela Sinilaite, Winnie Siu, Jesse Papenburg

{"title":"Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2023–2024","authors":"Angela Sinilaite, Winnie Siu, Jesse Papenburg","doi":"10.14745/ccdr.v49i10a01","DOIUrl":"https://doi.org/10.14745/ccdr.v49i10a01","url":null,"abstract":"Background: The National Advisory Committee on Immunization (NACI) reviews the evolving evidence on influenza immunization and provides annual recommendations regarding the use of seasonal influenza vaccines. The NACI Statement on Seasonal Influenza Vaccine for 2023–2024 updates the 2022–2023 NACI recommendations. Objective: To summarize the 2023–2024 NACI seasonal influenza vaccine recommendations and to highlight new and updated information. Methods: In the preparation of the Statement on Seasonal Influenza Vaccine for 2023–2024 , the NACI Influenza Working Group applied the NACI evidence-based process to critically appraise the available evidence and to propose recommendations. The recommendations were then considered and approved by NACI in light of the available evidence. Results: Key changes for the 2023–2024 season include: 1) incorporation of updated information/guidance on influenza vaccination in the context of the coronavirus disease 2019 (COVID-19); 2) new recommendations for Flucelvax ® Quad and Influvac ® Tetra, the two quadrivalent inactivated influenza vaccines with expanded paediatric age indications; and 3) an update to the format of the Statement. Conclusion: Overall, NACI continues to recommend that an age-appropriate influenza vaccine should be offered annually to all individuals aged six months and older who do not have a contraindication to the vaccine, with particular focus on the groups for whom influenza vaccination is particularly recommended.","PeriodicalId":33496,"journal":{"name":"Canada Communicable Disease Report","volume":"46 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139259221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics and clinical outcomes of nirmatrelvir/ritonavir (PaxlovidTM) recipients in Canada, 2022: a descriptive cohort study 2022 年加拿大接受尼马瑞韦/利托那韦（PaxlovidTM）治疗者的特征和临床疗效：一项描述性队列研究

Canada Communicable Disease Report Pub Date : 2023-11-20 DOI: 10.14745/ccdr.v49i10a05

Nadine Sicard, Susan Squires, Muhammad Mullah, Peter Daley

引用次数: 0

Healthcare costs and effects of post-COVID-19 condition in Canada 加拿大后 COVID-19 条件的医疗成本和影响

Canada Communicable Disease Report Pub Date : 2023-11-20 DOI: 10.14745/ccdr.v49i10a03

Ellen Rafferty, Ali Unsal, Erin Kirwin

{"title":"Healthcare costs and effects of post-COVID-19 condition in Canada","authors":"Ellen Rafferty, Ali Unsal, Erin Kirwin","doi":"10.14745/ccdr.v49i10a03","DOIUrl":"https://doi.org/10.14745/ccdr.v49i10a03","url":null,"abstract":"Background: As evidence of the long-term health impacts of coronavirus disease 2019 (COVID-19) continues to grow across Canada, a key concern is the costs and health impacts of post-COVID-19 condition (PCC), especially while the healthcare system remains under substantial strain. The objective of this study is to estimate healthcare costs and quality-adjusted life year (QALY) decrements per PCC case and per acute COVID-19 case by vaccination status. Methods: First, we conducted a rapid review of the literature to estimate 1) the probability of developing PCC following COVID-19 infection by vaccination status, 2) the probability of each condition commonly associated with PCC, 3) healthcare costs and QALY decrements associated with each condition and 4) the number of PCC cases currently in Canada. Second, using the data gathered from the literature, we built a tool to estimate the cost and QALY decrements per PCC and COVID-19 case. Results: Post-COVID-19 condition costs per COVID-19 case ranged from CAD 1,675 to CAD 7,340, and QALY decrements ranged between 0.047 to 0.206, in the first year following COVID-19 infection. Overall, individuals who were unvaccinated when they were infected had higher costs and QALY decrements. We estimated the total burden of PCC to the Canadian healthcare system based on PCC estimates up until spring 2023 would be between CAD 7.8 and CAD 50.6 billion. Conclusion: This article demonstrates the large potential health and economic burden of PCC for Canadians, and the importance of vaccination and other infection control strategies in reducing the longer-term costs and effects.","PeriodicalId":33496,"journal":{"name":"Canada Communicable Disease Report","volume":"194 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139255747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mise à jour du Comité consultatif national de l’immunisation (CCNI) sur l’épidémiologie de la méningococcie invasive (MI) et considérations pertinentes pour les programmes de prévention de la MI chez les personnes à haut risque d’exposition 国家免疫咨询委员会(CCNI)关于侵入性脑膜炎球菌病(im)流行病学和高风险暴露人群im预防规划的相关考虑的最新情况

Canada Communicable Disease Report Pub Date : 2023-09-25 DOI: 10.14745/ccdr.v49i09a01f

Anne Pham-Huy, Joseline Zafack, Courtney Primeau, Oliver Baclic, Marina Salvadori, Shelley Deeks

引用次数: 0